KR102606643B1 - N-(5-시아노-4-((2-메톡시에틸)아미노)피리딘-2-일)-7-포르밀-6-((4-메틸-2-옥소피페라진-1-일)메틸)-3,4-디히드로-1,8-나프티리딘-1(2h)-카르복스아미드의 입자 - Google Patents

N-(5-시아노-4-((2-메톡시에틸)아미노)피리딘-2-일)-7-포르밀-6-((4-메틸-2-옥소피페라진-1-일)메틸)-3,4-디히드로-1,8-나프티리딘-1(2h)-카르복스아미드의 입자 Download PDF

Info

Publication number
KR102606643B1
KR102606643B1 KR1020177026470A KR20177026470A KR102606643B1 KR 102606643 B1 KR102606643 B1 KR 102606643B1 KR 1020177026470 A KR1020177026470 A KR 1020177026470A KR 20177026470 A KR20177026470 A KR 20177026470A KR 102606643 B1 KR102606643 B1 KR 102606643B1
Authority
KR
South Korea
Prior art keywords
methyl
amino
naphthyridine
methoxyethyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177026470A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129758A (ko
Inventor
니콜 부쉬만
로빈 알렉 페어허스트
파스칼 푸레
토마스 크뇌펠
캐서린 르블랑
로버트 마
프랑크 말레
줄리 마츠
레브 리아오
징 시옹
보 한
칸 왕
시앙린 자오
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20170129758A publication Critical patent/KR20170129758A/ko
Application granted granted Critical
Publication of KR102606643B1 publication Critical patent/KR102606643B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177026470A 2015-03-25 2016-03-23 N-(5-시아노-4-((2-메톡시에틸)아미노)피리딘-2-일)-7-포르밀-6-((4-메틸-2-옥소피페라진-1-일)메틸)-3,4-디히드로-1,8-나프티리딘-1(2h)-카르복스아미드의 입자 Active KR102606643B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015000202 2015-03-25
CNPCT/CN2015/000202 2015-03-25
PCT/IB2016/051633 WO2016151500A1 (en) 2015-03-25 2016-03-23 Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide

Publications (2)

Publication Number Publication Date
KR20170129758A KR20170129758A (ko) 2017-11-27
KR102606643B1 true KR102606643B1 (ko) 2023-11-28

Family

ID=55637404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026470A Active KR102606643B1 (ko) 2015-03-25 2016-03-23 N-(5-시아노-4-((2-메톡시에틸)아미노)피리딘-2-일)-7-포르밀-6-((4-메틸-2-옥소피페라진-1-일)메틸)-3,4-디히드로-1,8-나프티리딘-1(2h)-카르복스아미드의 입자

Country Status (14)

Country Link
US (1) US9802917B2 (https=)
EP (1) EP3274349B1 (https=)
JP (1) JP6696995B2 (https=)
KR (1) KR102606643B1 (https=)
CN (1) CN107406448B (https=)
AR (1) AR104060A1 (https=)
AU (2) AU2016238437B2 (https=)
CA (1) CA2977326C (https=)
ES (1) ES2803028T3 (https=)
MX (1) MX2017012293A (https=)
PL (1) PL3274349T3 (https=)
RU (1) RU2720456C2 (https=)
TW (1) TWI699206B (https=)
WO (1) WO2016151500A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6585167B2 (ja) * 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
CN113234072B (zh) * 2016-05-20 2022-11-04 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CA3075720A1 (en) * 2017-10-02 2019-04-11 Novartis Ag Method for preparing a pharmaceutical product
CN110234649B (zh) * 2017-10-31 2021-10-15 江苏豪森药业集团有限公司 Fgfr4抑制剂的盐、晶体、制备方法及其用途
WO2019085860A1 (zh) * 2017-10-31 2019-05-09 江苏豪森药业集团有限公司 Fgfr4抑制剂晶型及其制备方法
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物
AU2020298246A1 (en) * 2019-06-21 2022-01-27 Terns Pharmaceuticals Inc. Compounds for inhibiting FGFR4

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511563A (ja) 2002-12-20 2006-04-06 エフ．ホフマン−ラ　ロシュ　アーゲー 選択的ｋｄｒ及びｆｇｆｒインヒビターとしてのピリジノ［２，３−ｄ］ピリミジン誘導体
JP2012180344A (ja) 2011-02-07 2012-09-20 Chugai Pharmaceut Co Ltd アミノピラゾール誘導体を含む医薬
JP2012524055A (ja) 2009-04-15 2012-10-11 アステックス、セラピューティックス、リミテッド 治療用途のためのｆｇｆｒキナーゼ阻害薬としての二環式へテロシクリル誘導体
WO2013061080A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Anticancer pyridopyrazines via the inhibition of fgfr kinases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
CA2261633A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
ES2241192T3 (es) 1997-12-17 2005-10-16 MERCK & CO., INC. (A NEW JERSEY CORP.) Antagonistas del receptor de integrina.
AR015514A1 (es) 1998-02-10 2001-05-02 Novartis Ag Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JPWO2003068753A1 (ja) 2002-02-14 2005-06-02 小野薬品工業株式会社 Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2003303231A1 (en) 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1613322A4 (en) 2003-04-11 2008-08-13 Taigen Biotechnology Co Ltd AMINOQUINOLINE COMPOUNDS
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
CN101223167B (zh) 2005-07-15 2011-08-31 弗·哈夫曼-拉罗切有限公司 杂芳基稠合的环状胺
BRPI0620408B8 (pt) 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
EP1976528A2 (en) 2005-12-29 2008-10-08 Janssen Pharmaceutica, N.V. Prokineticin 2 receptor antagonists
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
CA2679268A1 (en) 2007-03-09 2008-09-18 Novartis Ag Treatment of melanoma
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
RU2561109C2 (ru) 2008-12-19 2015-08-20 Дженентек, Инк. Соединения и способы применения
CA2761009A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
CN102596916B (zh) 2009-10-30 2015-06-17 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
AP2013007153A0 (en) 2011-03-18 2013-09-30 Lupin Ltd Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US20150290235A1 (en) 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASEHEMMER FOR THE TREATMENT OF DISEASES
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
MX378288B (es) 2013-10-18 2025-03-10 Eisai R&D Man Co Ltd Inhibidores de pirimidina del fgfr4.
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN105683188B (zh) * 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511563A (ja) 2002-12-20 2006-04-06 エフ．ホフマン−ラ　ロシュ　アーゲー 選択的ｋｄｒ及びｆｇｆｒインヒビターとしてのピリジノ［２，３−ｄ］ピリミジン誘導体
JP2012524055A (ja) 2009-04-15 2012-10-11 アステックス、セラピューティックス、リミテッド 治療用途のためのｆｇｆｒキナーゼ阻害薬としての二環式へテロシクリル誘導体
JP2012180344A (ja) 2011-02-07 2012-09-20 Chugai Pharmaceut Co Ltd アミノピラゾール誘導体を含む医薬
WO2013061080A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Anticancer pyridopyrazines via the inhibition of fgfr kinases

Also Published As

Publication number Publication date
TWI699206B (zh) 2020-07-21
RU2017133243A3 (https=) 2019-07-29
EP3274349B1 (en) 2020-04-22
AU2019200936A1 (en) 2019-02-28
AU2016238437A1 (en) 2017-08-17
CA2977326A1 (en) 2016-09-29
AR104060A1 (es) 2017-06-21
BR112017016991A2 (pt) 2018-04-10
CN107406448B (zh) 2021-03-09
AU2016238437B2 (en) 2018-11-08
KR20170129758A (ko) 2017-11-27
EP3274349A1 (en) 2018-01-31
TW201641106A (zh) 2016-12-01
MX2017012293A (es) 2018-01-09
PL3274349T3 (pl) 2020-10-05
CA2977326C (en) 2023-08-29
JP2018509446A (ja) 2018-04-05
WO2016151500A1 (en) 2016-09-29
US9802917B2 (en) 2017-10-31
JP6696995B2 (ja) 2020-05-20
ES2803028T3 (es) 2021-01-22
RU2720456C2 (ru) 2020-04-30
RU2017133243A (ru) 2019-04-05
US20160304489A1 (en) 2016-10-20
CN107406448A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
KR102606643B1 (ko) N-(5-시아노-4-((2-메톡시에틸)아미노)피리딘-2-일)-7-포르밀-6-((4-메틸-2-옥소피페라진-1-일)메틸)-3,4-디히드로-1,8-나프티리딘-1(2h)-카르복스아미드의 입자
TWI750188B (zh) 用於製備經取代多環吡啶酮衍生物之方法及其結晶
US7304059B2 (en) Substituted quinazolin-4-ylamine analogues
JP5537417B2 (ja) Ｃｒｔｈ２及び／又はｐｇｄ２受容体調節物質としての化合物、並びにぜん息及びアレルギー性炎症を治療するためのその使用
JP5845215B2 (ja) 複素環化合物およびその使用
TWI648274B (zh) 作為激酶抑制劑之雜環醯胺類 （二）
AU2008289037B2 (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
JP2005534636A (ja) プロテインキナーゼ依存性疾患の処置における１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体
JP2008528506A (ja) ヘテロアリール置換ピペラジニル−ピリジン類縁体
JP2005527622A (ja) プロテインキナーゼ依存性疾患の処置に有用なジアリールウレア誘導体
EP1751153A1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MX2013006284A (es) Derivados sustituidos de imidazoquinolina.
JP2008526997A (ja) ヘテロアリール置換キノリン−４−イルアミン類縁体
JP2008528613A (ja) 置換ピリダジニル−及びピリミジニル−キノリン−４−イルアミン類縁体
TW201902892A (zh) 化合物
CN117529481B (zh) Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
BR112017016991B1 (pt) Partículas de n-(5-ciano-4-((2-metóxi-etil)amino)piridin-2-il)-7-formil-6-((4- metil-2-oxopiperazin-1-il)metil)-3,4-di-hidro-1,8-naftiridina-1(2h)-carboxamida, seu uso e seu processo de preparação, aglomerado, e composição farmacêutica
WO2015162584A1 (en) Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
AU2003205217A1 (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
HK40008147A (en) Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601